Carles Codony-Servat
Overview
Explore the profile of Carles Codony-Servat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony-Servat C, et al.
Sci Rep
. 2023 Mar;
13(1):3620.
PMID: 36869103
No abstract available.
2.
Attili I, Bonanno L, Karachaliou N, Bracht J, Berenguer J, Codony-Servat C, et al.
Transl Lung Cancer Res
. 2020 Nov;
9(5):1810-1821.
PMID: 33209603
Background: The role of MET alterations in non-small cell lung cancer (NSCLC) is increasing and several targeted agents are under evaluation. MET exon 14 skipping mutations and MET amplifications are...
3.
Bracht J, Karachaliou N, Berenguer J, Pedraz-Valdunciel C, Filipska M, Codony-Servat C, et al.
Int J Biol Sci
. 2019 Nov;
15(12):2607-2614.
PMID: 31754333
Monotherapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) still leads to incomplete responses in most EGFR-mutation positive non-small cell lung cancer (NSCLC) patients, often due to acquired...
4.
Ito M, Codony-Servat C, Karachaliou N, Rosell R
Transl Lung Cancer Res
. 2019 Nov;
8(5):667-673.
PMID: 31737502
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). However, universal progression is observed. Methods: The effect of...
5.
Ito M, Codony-Servat C, Codony-Servat J, Llige D, Chaib I, Sun X, et al.
Cell Commun Signal
. 2019 Oct;
17(1):137.
PMID: 31660987
Introduction: p21-activated kinase 1 (PAK1) stimulates growth and metastasis in non-small cell lung cancer (NSCLC). Protein kinase C iota (PKCι) is an enzyme highly expressed in NSCLC, regulating PAK1 signaling....
6.
Codony-Servat J, Viteri S, Codony-Servat C, Ito M, Bracht J, Berenguer J, et al.
Transl Lung Cancer Res
. 2019 Sep;
8(4):340-351.
PMID: 31555510
Background: Osimertinib improve therapy for non-small cell lung cancer (NSCLC). However, invariable acquired resistance appears. Methods: MTT assay was used to analyze cell viability. Protein expression and activation was detected...
7.
Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Gimenez-Capitan A, Cantero F, et al.
Nat Commun
. 2019 Apr;
10(1):1812.
PMID: 31000705
Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M...
8.
Codony-Servat J, Codony-Servat C, Cardona A, Gimenez-Capitan A, Drozdowskyj A, Berenguer J, et al.
Clin Lung Cancer
. 2019 Mar;
20(3):167-177.
PMID: 30885551
Introduction: Epidermal growth factor receptor (EGFR) pathway deregulation promotes the acquisition of stemlike properties in non-small-cell lung cancer. EGFR inhibition through NOTCH enriches lung cancer stem cells (CSCs). Src through...
9.
Rosell R, Karachaliou N, Codony-Servat C, Ito M
Transl Lung Cancer Res
. 2018 Nov;
7(Suppl 3):S183-S186.
PMID: 30393596
No abstract available.
10.
Attili I, Karachaliou N, Bonanno L, Berenguer J, Bracht J, Codony-Servat J, et al.
Ther Adv Med Oncol
. 2018 Apr;
10:1758835918763744.
PMID: 29636826
Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the...